Download
TMH526786.pdf 203,90KB
WeightNameValue
1000 Titel
  • Regulatory Measures to Improve the Safety of CAR-T-Cell Treatment
1000 Autor/in
  1. Berg, Philipp |
  2. Schönefeld, Sonja |
  3. Ruppert-Seipp, Gabriele |
  4. Funk, Markus |
1000 Verlag S. Karger AG
1000 Erscheinungsjahr 2022
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2022-11-29
1000 Erschienen in
1000 Quellenangabe
  • 50(3):218-225
1000 Copyrightjahr
  • 2022
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1159/000526786 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331154/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:p>Introduction: Regulatory activities aim to facilitate the safe use of novel therapeutics such as genetically engineered chimeric antigen receptor (CAR)-T cells. Toxicities associated with CAR-T-cell therapies have led to modified safety management guidance in clinical trials and the implementation of post-marketing requirements. The aim of this study was to estimate the effect of individual risk-minimizing measures to evaluate the appropriateness of regulatory activities. Methods: We re-examined clinical trial data prior to and after the introduction of revised treatment guidelines; we analysed spontaneous adverse drug reaction (ADR) reports submitted to the EudraVigilance database in 2019/2020 regarding their completeness; and we performed a survey of treatment centres in Germany that have been qualified for the use of commercial CAR-T cells. Results: Lower combined incidences of severe cytokine release syndrome (CRS) as well as neurotoxicity occurred following CAR-T-cell treatment after a revision of management guidelines, suggesting earlier intervention compared to before (12.6% vs. 20.5%). Numerous post-marketing ADR reports lacked information important for case assessment. Full details on treatment indication, CRS onset, outcome, and grading were available for just 38.3% of CRS cases. Survey responses support the majority of regulatory requirements for centre qualification. Time investment was highest for training of healthcare professionals, which required an average of 6.5 staff members (range 2–20) and lasted more than 2 days per person in half of the facilities. The need to harmonize the regulatory requirements for the different CAR-T-cell therapeutics was emphasized. Conclusion: Defined regulatory measures can support the safe and effective use of new therapies and are indicated for structured recording of post-marketing data, and the evaluation of such measures appears to be necessary for the continuous improvement. </jats:p>
1000 Sacherschließung
lokal Advanced therapy regulation
lokal Risk minimization
lokal Cytokine release syndrome
lokal Pharmacovigilance
lokal Chimeric antigen receptor-T-cell safety
lokal Research Article
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0003-0674-9031|https://frl.publisso.de/adhoc/uri/U2Now7ZuZWZlbGQsIFNvbmph|https://orcid.org/0000-0002-6141-1386|https://orcid.org/0000-0001-8642-1276
1000 Hinweis
  • DeepGreen-ID: 11ff6098392f43e792be5e77c0b078d4 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6486867.rdf
1000 Erstellt am 2024-10-03T04:00:16.132+0200
1000 Erstellt von 322
1000 beschreibt frl:6486867
1000 Zuletzt bearbeitet 2025-08-13T22:51:28.542+0200
1000 Objekt bearb. Wed Aug 13 22:51:28 CEST 2025
1000 Vgl. frl:6486867
1000 Oai Id
  1. oai:frl.publisso.de:frl:6486867 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source